Rodman & Renshaw started coverage on shares of Actuate Therapeutics (NASDAQ:ACTU – Get Free Report) in a report issued on Thursday,Benzinga reports. Weiss Ratings restated a “sell (e+)” rating on shares of Actuate Therapeutics in a research note on Wednesday, June 24th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Actuate Therapeutics in a research report on Wednesday, June 10th. Get Actuate Therapeutics alerts:Read Our Latest Report on Actuate TherapeuticsActuate Therapeutics Price PerformanceActuate Therapeutics stock opened at $1.08 on Thursday. Recommended StoriesReceive News & Ratings for Actuate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actuate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.